FDA’s Executive Forum on the “Case for Quality Initiative” brought together Industry Executives, FDA Officials and Industry Advisors in a series of roundtable discussions and presentations. Axendia had the unique opportunity to participate in this exceptional event.
The Executive Forum afforded participants the opportunity to have open, candid, and constructive discussions on ways to improve interactions between industry and FDA. Participants also identified barriers to investment in prevention and product quality, generating actionable ideas to overcome these barriers, and building a stronger partnership between FDA and industry. Executives, Regulators and thought leaders shared their experiences and approaches to driving higher product quality
Presenters at the Case for quality Executive Forum included (in alphabetical order):
- Axendia
- Boston Scientific
- Covidien
- FDA CDRH
- FDA ORA
- McKinsey & Company
- MedAccred
- Terumo Cardiovascular Systems
Click on this link to read the full report on FDA’s Executive Forum on the “Case for Quality Initiative.”
To learn more about the Case for Quality Initiative, read our interview series with Steve Silverman, Director of the Office of Compliance at FDA’s CDRH.